CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three months and year ended December 31, 2014, and provided an update of recent corporate developments.
“Last month we released 168 week data from our Phase IIb study of eteplirsen. We believe the long-term safety of our drug with the continued ambulation and stability of pulmonary function in these boys are encouraging considering the length of follow up and the advancing age of the boys,” said Chris Garabedian, president and chief executive officer.
Help employers find you! Check out all the jobs and post your resume.
